SevoFlo

1 x 250 ml

Inhalation, solution

Active substance

Sevoflurane : 100 %

ATC code

QN01AB08 Sevoflurane

QN01AB Halogenated hydrocarbons

QN01A Anesthetics, general

QN01 Anesthetics

QN Nervous system

Species

Dogs and cats.

Indications

For the induction and maintenance of anaesthesia.

Dose to be administered and administration route

Inspired concentration:

The veterinary medicinal product should be administered via a vaporiser specifically calibrated for use with sevoflurane so that the concentration delivered can be accurately controlled. The veterinary medicinal product contains no stabiliser and does not affect the calibration or operation of these vaporisers in any way. The administration of sevoflurane must be individualised based on the dog’s or cat’s response.

Premedication:

The necessity for and choice of premedication is left to the discretion of the veterinarian. Preanaesthetic doses for premedicants may be lower than the label directions for their use as a single medication.

Induction of anaesthesia:

For mask induction using sevoflurane, inspired concentrations of 5 to 7% sevoflurane with oxygen are employed to induce surgical anaesthesia in the healthy dog, and 6 to 8% sevoflurane with oxygen in the cat. These concentrations can be expected to produce surgical anaesthesia within 3 to 14 minutes in dogs and within 2 to 3 minutes in cats. Sevoflurane concentration for induction may be set initially, or may be achieved gradually over the course of 1 to 2 minutes. The use of premedicants does not affect the concentration of sevoflurane required for induction.

Maintenance of anaesthesia:

Sevoflurane may be used for maintenance anaesthesia following mask induction with sevoflurane or following induction with injectable agents. The concentration of sevoflurane necessary to maintain anaesthesia is less than that required for induction.

Surgical levels of anaesthesia in the healthy dog may be maintained with inhaled concentrations of 3.3 to 3.6% in the presence of premedication. In the absence of premedication, inhaled concentrations of sevoflurane in the range 3.7 to 3.8% will provide surgical levels of anaesthesia in the healthy dog. In the cat surgical anaesthesia is maintained with sevoflurane concentrations of 3.7-4.5%. The presence of surgical stimulation may require an increase in the concentration of sevoflurane. The use of injectable induction agents without premedication has little effect on the concentrations of sevoflurane required for maintenance. Anaesthetic regimens that include opioid, alpha-2-agonist, benzodiazepine or phenothiazine premedication will allow the use of lower sevoflurane maintenance concentrations.

Adverse reactions

Dogs and cats:

Very common

(>1 animal / 10 animals treated):

Hypotension¹

Elevated alanine aminotransferase (ALT)^2,3, elevated aspartate aminotransferase (AST)^2,3, elevated lactate dehydrogenase (LDH)^2,4, elevated total bilirubin^2,4

Leucocytosis^2,4

Tense muscles, fasciculation

Excitation

Tachypnoea, apnoea

Emesis

Common

(1 to 10 animals / 100 animals treated):

Respiratory depression⁵ Bradycardia⁶

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Paddling

Retching, increased salivation

Cyanosis

Premature ventricular contractions, cardiac depression⁷

Respiratory depression⁷

Malignant hyperthermia⁸

¹ hypotension during sevoflurane anaesthesia may result in decreased renal blood flow.

² in dogs transient elevations in AST, ALT, LDH, bilirubin and white blood cell counts may occur.

³ in cats transient increases in AST and ALT may occur, however hepatic enzymes tend to remain within the normal range.

⁴ dogs only.

⁵ respiratory depression is dose-dependent; therefore, respiration should be closely monitored during sevoflurane anaesthesia and the inspired concentration of sevoflurane adjusted accordingly.

⁶ anaesthetic-induced bradycardia may be reversed by administration of anticholinergics.

⁷ excessive cardiopulmonary depression.

⁸ the possibility of sevoflurane triggering episodes of malignant hyperthermia in susceptible dogs and cats cannot be ruled out.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.